<DOC>
	<DOCNO>NCT00006375</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness LY293111 treat patient advance solid tumor .</brief_summary>
	<brief_title>LY293111 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose LY293111 patient advance solid tumor . II . Determine safety profile pharmacokinetics regimen patient . III . Determine antitumor activity regimen patient . OUTLINE : This dose escalation study . Patients receive oral LY293111 twice daily . Treatment continue maximum 6 month absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos LY293111 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose limit toxicity . Additional patient treat MTD . Patients follow 30 day . PROJECTED ACCRUAL : Approximately 24 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced and/or metastatic solid tumor curative therapy exist No hematologic malignancy Measurable evaluable disease No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT AST great 2.0 time ULN Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No concurrent systemic disorder would preclude study No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent immunotherapy Chemotherapy : No 3 prior chemotherapy regimens metastatic disease At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : At least 4 week since prior anticancer hormonal therapy recover No concurrent anticancer hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since prior investigational therapy No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>